LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Celgene Corporation (“Celgene” or the “Company) (NASDAQ: CELG) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Celgene investigation page on our website at www.glancylaw.com/case/celgene-corporation.
On February 27, 2018, Celgene announced that the FDA rejected the Company’s New Drug Application (“NDA”) for Ozanimod, a treatment for multiple sclerosis. Celgene stated that it had received a refusal-to-file letter from the FDA, which advised the Company that the FDA had “determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.” On this news, Celgene’s share price fell $8.66, or 9%, on February 28, 2018, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Celgene securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.